Nanping

Researchers are studying the safety and effectiveness of starting direct oral anticoagulants DOACs early versus delaying their start in adults who have had an acute ischemic stroke related to atrial fibrillation and received emergency endovascular therapy EVT. This trial is a multicenter, randomized controlled study designed to compare different timings for beginning DOAC treatment after stroke. Participants are randomly assigned to one of two groups. One group will begin taking any DOAC within 96 hours 4 days of stroke onset, while the other group will start DOAC treatment between 5 and 14 days after stroke onset. The study compares these two approaches to see which timing is safer and more effective. During the study, participants will be monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Researchers will also assess other events like venous clots, heart attacks, and overall quality of life. Follow-up visits and assessments will track these health outcomes and safety measures throughout the study period, which lasts up to one year for some outcomes.

Researchers are evaluating the safety and effectiveness of starting direct oral anticoagulants DOACs early versus delayed in patients who have an acute ischemic stroke related to atrial fibrillation and develop bleeding in the brain after emergency endovascular treatment. This multicenter, open-label, randomized controlled trial focuses on the best timing to begin DOAC therapy to help manage these patients and reduce risks of complications such as recurrent stroke or bleeding. Participants will be randomly assigned to one of two groups an early anticoagulation group starting DOACs within 4 weeks of stroke onset, and a delayed anticoagulation group starting DOACs between 4 and 8 weeks after stroke onset. The study compares these two approaches to determine which timing is safer and more effective for this condition. The treatments involve any direct oral anticoagulant drug, and the trial is conducted at multiple centers with an open-label design. During the study, participants will be closely monitored for outcomes including recurrent ischemic stroke, symptomatic brain bleeding, and death over 90 days. Other assessments include measuring quality of life, hospital stay length, vascular events, and functional recovery using the modified Rankin scale. Researchers will collect data through imaging, clinical evaluations, and questionnaires. Follow-up is planned for 90 days after starting treatment to assess safety and overall health outcomes.